These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 23672220)

  • 41. Nateglinide and acarbose are comparably effective reducers of postprandial glycemic excursions in chinese antihyperglycemic agent-naive subjects with type 2 diabetes.
    Zhou J; Li H; Zhang X; Peng Y; Mo Y; Bao Y; Jia W
    Diabetes Technol Ther; 2013 Jun; 15(6):481-8. PubMed ID: 23631607
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of acarbose and metformin in patients with Type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: a randomized, placebo-controlled study.
    Willms B; Ruge D
    Diabet Med; 1999 Sep; 16(9):755-61. PubMed ID: 10510952
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of acarbose and voglibose in diabetes patients who are inadequately controlled with basal insulin treatment: randomized, parallel, open-label, active-controlled study.
    Lee MY; Choi DS; Lee MK; Lee HW; Park TS; Kim DM; Chung CH; Kim DK; Kim IJ; Jang HC; Park YS; Kwon HS; Lee SH; Shin HK
    J Korean Med Sci; 2014 Jan; 29(1):90-7. PubMed ID: 24431911
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Randomized, Double-Blinded, Double-Dummy, Active-Controlled, and Multiple-Dose Clinical Study Comparing the Efficacy and Safety of Mulberry Twig (Ramulus Mori, Sangzhi) Alkaloid Tablet and Acarbose in Individuals with Type 2 Diabetes Mellitus.
    Li M; Huang X; Ye H; Chen Y; Yu J; Yang J; Zhang X
    Evid Based Complement Alternat Med; 2016; 2016():7121356. PubMed ID: 27547230
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Durability of efficacy and long-term safety profile of glyburide/metformin tablets in patients with type 2 diabetes mellitus: an open-label extension study.
    Garber AJ; Bruce S; Fiedorek FT
    Clin Ther; 2002 Sep; 24(9):1401-13. PubMed ID: 12380632
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of Metformin-sulfonylurea and Metformin-acarbose Combination Therapies on Glycemic Outcomes: A Retrospective Cohort Study.
    Wafa W; Septini R; Sauriasari R
    Curr Diabetes Rev; 2022; 18(7):e031121197656. PubMed ID: 34732117
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of acarbose on additional insulin therapy in type 2 diabetic patients with late failure of sulphonylurea therapy.
    Standl E; Baumgartl HJ; Füchtenbusch M; Stemplinger J
    Diabetes Obes Metab; 1999 Jul; 1(4):215-20. PubMed ID: 11228756
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Acarbose Add-on Therapy in Patients with Type 2 Diabetes Mellitus with Metformin and Sitagliptin Failure: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study.
    Yang HK; Lee SH; Shin J; Choi YH; Ahn YB; Lee BW; Rhee EJ; Min KW; Yoon KH
    Diabetes Metab J; 2019 Jun; 43(3):287-301. PubMed ID: 30604599
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Glycemic control with Humalog Mix25 in type 2 diabetes inadequately controlled with glyburide.
    Roach ; Koledova E; Metcalfe S; Hultman C; Milicevic Z;
    Clin Ther; 2001 Oct; 23(10):1732-44. PubMed ID: 11726007
    [TBL] [Abstract][Full Text] [Related]  

  • 50. RETRACTED: Acarbose on insulin resistance after an oral fat load: a double-blind, placebo controlled study.
    Derosa G; Maffioli P; D'Angelo A; Fogari E; Bianchi L; Cicero AF
    J Diabetes Complications; 2011; 25(4):258-66. PubMed ID: 21367625
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients.
    Bayraktar M; Van Thiel DH; Adalar N
    Diabetes Care; 1996 Mar; 19(3):252-4. PubMed ID: 8742572
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Renal Outcomes of Pioglitazone Compared with Acarbose in Diabetic Patients: A Randomized Controlled Study.
    Chen YH; Tarng DC; Chen HS
    PLoS One; 2016; 11(11):e0165750. PubMed ID: 27812149
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus.
    Coniff RF; Shapiro JA; Seaton TB; Bray GA
    Am J Med; 1995 May; 98(5):443-51. PubMed ID: 7733122
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study.
    Ji L; Ma J; Li H; Mansfield TA; T'joen CL; Iqbal N; Ptaszynska A; List JF
    Clin Ther; 2014 Jan; 36(1):84-100.e9. PubMed ID: 24378206
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of metformin and sitagliptin based triple antihyperglycemic therapy (STRATEGY): a multicenter, randomized, controlled, non-inferiority clinical trial.
    Xu W; Mu Y; Zhao J; Zhu D; Ji Q; Zhou Z; Yao B; Mao A; Engel SS; Zhao B; Bi Y; Zeng L; Ran X; Lu J; Ji L; Yang W; Jia W; Weng J
    Sci China Life Sci; 2017 Mar; 60(3):225-238. PubMed ID: 28271251
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial.
    Derosa G; Salvadeo SA; D'Angelo A; Ferrari I; Mereu R; Palumbo I; Maffioli P; Randazzo S; Cicero AF
    Curr Med Res Opin; 2009 Mar; 25(3):607-15. PubMed ID: 19232035
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Acarbose and metabolic control in patients with type 2 diabetes with newly initiated insulin therapy.
    Schnell O; Mertes G; Standl E;
    Diabetes Obes Metab; 2007 Nov; 9(6):853-8. PubMed ID: 17924867
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The beneficial effect of α-glucosidase inhibitor on glucose variability compared with sulfonylurea in Taiwanese type 2 diabetic patients inadequately controlled with metformin: preliminary data.
    Lin SD; Wang JS; Hsu SR; Sheu WH; Tu ST; Lee IT; Su SL; Lin SY; Wang SY; Hsieh MC
    J Diabetes Complications; 2011; 25(5):332-8. PubMed ID: 21813293
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1-year multicentre study.
    Madsbad S; Kilhovd B; Lager I; Mustajoki P; Dejgaard A;
    Diabet Med; 2001 May; 18(5):395-401. PubMed ID: 11472451
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Post-marketing surveillance of acarbose treatment in patients with type 2 diabetes mellitus and subjects with impaired glucose tolerance in China.
    Pan CY; Landen H
    Clin Drug Investig; 2007; 27(6):397-405. PubMed ID: 17506590
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.